Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | NCS1 | P62166 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897642 | 0.92 | TRPV1 (0.50) | TRPV1DYRK1ANCS1AKR1B1ALOX5 | |
| SCHEMBL4902624 | 0.85 | SMN1; SMN2 (0.53) | GAAALDH1A1 | |
| SCHEMBL5391125 | 0.82 | TRPV1 (0.56) | TRPV1DYRK1ANCS1AKR1B1ALOX5 | |
| SCHEMBL14423962 | 0.79 | TRPV1 (0.52) | TRPV1AGPAT2GAAALDH1A1 | |
| SCHEMBL4905942 | 0.78 | DYRK1A (0.41) | TRPV1DYRK1ANCS1AKR1B1ALOX5 | |
| SCHEMBL4905529 | 0.78 | MAPT (0.45) | GAAALDH1A1 | |
| SCHEMBL4894513 | 0.77 | HTT (0.48) | GAAALDH1A1 | |
| SCHEMBL4906718 | 0.77 | TP53 (0.48) | GAAALDH1A1 | |
| SCHEMBL4906494 | 0.76 | LMNA (0.56) | GAAALDH1A1 | |
| SCHEMBL4902600 | 0.76 | LMNA (0.64) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | TRPV1 3358/4885DYRK1A 3126/4885NCS1 4540/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | TRPV1 3397/4885DYRK1A 3237/4885NCS1 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.